Rare and neglected diseases often face unique obstacles such as small patient populations, limited clinical data, sensitive patient populations, and complex regulatory pathways. Certara integrates model-informed drug development (MIDD) approaches, including pharmacometrics, to overcome the unique challenges of rare disease drug development. By leveraging advanced modeling, simulation, and regulatory expertise, we enable data-driven decisions in small, complex patient populations.
In rare disease programs where patient numbers are limited, pharmacometrics and MIDD approaches are essential to extract maximum value from available data, enabling robust decision-making across development and regulatory milestones.
